Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Proc Natl Acad Sci U S A
Κύριοι συγγραφείς: Kaye, Joel, Piryatinsky, Victor, Birnberg, Tal, Hingaly, Tal, Raymond, Emanuel, Kashi, Rina, Amit-Romach, Einat, Caballero, Ignacio S., Towfic, Fadi, Ator, Mark A., Rubinstein, Efrat, Laifenfeld, Daphna, Orbach, Aric, Shinar, Doron, Marantz, Yael, Grossman, Iris, Knappertz, Volker, Hayden, Michael R., Laufer, Ralph
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: National Academy of Sciences 2016
Θέματα:
PNAS Plus
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5068259/
https://ncbi.nlm.nih.gov/pubmed/27671624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607843113
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια